Cargando…
Short-term Outcomes After Upfront Chemotherapy Followed by Curative Surgery in Metastatic Colon Cancer: A Comparison With Upfront Surgery Patients
PURPOSE: Upfront systemic chemotherapy with target agents has been recommended for patients with stage IV colon cancer. Some with partial response are considered for curative resection. There is high risk of developing postoperative complications following upfront systemic chemotherapy. We aimed to...
Autores principales: | Han, Myung Hyun, Park, Youn Young, Pratap, Shiva, Han, Yoon Dae, Cho, Min Soo, Hur, Hyuk, Min, Byung Soh, Lee, Kang Young, Kim, Nam Kyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Coloproctology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968719/ https://www.ncbi.nlm.nih.gov/pubmed/31937072 http://dx.doi.org/10.3393/ac.2019.03.04.1 |
Ejemplares similares
-
Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases
por: Shin, Sang Joon, et al.
Publicado: (2011) -
Surgery for Crohn’s disease: upfront or last resort?
por: Ahmed Ali, U, et al.
Publicado: (2022) -
Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
por: Lee, Jii Bum, et al.
Publicado: (2020) -
Upfront surgery of small intestinal neuroendocrine tumors. Time to reconsider?
por: Daskalakis, Kosmas, et al.
Publicado: (2018) -
Ogilvie’s syndrome—is there a cutoff diameter to proceed with upfront surgery?
por: Joechle, Katharina, et al.
Publicado: (2022)